Company intelligence / Profile preview

Drug Farm

Ownership: Private
Development stage: Other

Overview

Drug Farm has advanced multiple first-in-class drug candidates into clinical development using its proprietary IDInVivo platform. Lead candidate DF‑006, an orally administered ALPK1 agonist immunomodulator targeting innate immunity in the liver, has completed single/multiple ascending dose studies in healthy volunteers and chronic hepatitis B patients with encouraging anti-HBV activity observed. Another candidate, DF‑003 targeting ALPK1 for ROSAH syndrome and related disorders, has completed Phase 1 safety studies.

Therapeutic areas: Rare DiseasesInfectious DiseasesOphthalmologyGastroenterologyOncologyNephrologyCardiovascular
Modalities: Small moleculeMonoclonal antibodyImmunomodulatorAgonist
Industry: Biotech

Drug pipeline

9 assets

PG201

8 more assets in the full pipeline.

Partnerships

Amoytop/Xiamen Amoytop Biotech Co., Ltd.National Institutes of Health

Beyond the preview

Go deeper on Drug Farm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Drug Farm.